NASDAQ: RVPH

Reviva Pharmaceuticals Holdings, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public.

If you purchased Reviva Pharmaceuticals securities and would like to join the prospective action, please click “Join This Class Action.”

Retainer Agreement
See Full Details
Join This Class Action
If you purchased Reviva Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 15, 2024, Reviva Pharmaceuticals filed with the SEC a current report on Form 8-K. In this current report, Reviva Pharmaceuticals announced that “the Company’s previously issued financial statements for the fiscal year ended December 31, 2022 included in its Annual Report on Form 10-K, the interim financial statements for the quarterly period ended September 30, 2022 included in its Quarterly Report on Form 10-Q, and each of the interim financial statements for the quarterly periods in fiscal 2023 included in its Quarterly Reports on Form 10-Q (cumulatively, the “Restatement Periods”) should be restated to correct historical errors related principally to the timing of recognition of the Company’s estimated accrual of certain research and development expenses, and should therefore no longer be relied upon.”

On this news, Reviva Pharmaceuticals’ stock fell $0.21 per share, or 5.7%, to close at $3.48 per share on April 15, 2024.

Follow us on:
Twitter
Company Name: Reviva Pharmaceuticals Holdings, Inc.
Stock Symbol: RVPH
Class Period: N/A
Court: N/A
Share This Class Action
Join This Class Action

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Case Attorneys

Phillip Kim

New York, Philadelphia Metro

275 Madison Avenue
40th Floor
New York, NY 10016

Tel: (212) 686-1060
Privacy Policy | Accessibility
Scroll to Top